Take a look at CSL Behring's production of high-quality Ig products.
Submit via fax to confirm a patient's coverage options for Privigen.
A guide to IgIQ, a support center that manages Ig product–related information and assists with enrollment in CSL Behring patient support programs.
Stein MR, Nelson RP, Church JA, et al; for the IgPro10 in PID study group. Safety and efficacy of Privigen®, a novel 10% liquid immunoglobulin preparation for intravenous use, in patients with primary immunodeficiencies.
Church JA, Borte M, Taki H, et al. Efficacy and safety of Privigen in children and adolescents with primary immunodeficiency.
Leger J-M, De Bleecker JL, Sommer C, et al. Efficacy and safety of Privigen® in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single-arm, open-label Phase III study (the PRIMA study).